AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2058612
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (both doses)
Trial: 6222636
Drug: FK 33-824
RxNorm normalized name: FK-960
DrugBank: FK-960 (DB06465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK 33-824 (2 mg)
Trial: 23467551
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate in MLE cream
Trial: 18670308
Drug: Larotaxel (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larotaxel (50 mg/m) + cisplatin (75 mg/m) every 3 weeks (arm A)
Trial: 18670308
Drug: Larotaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larotaxel (60 mg/m) + gemcitabine (800 mg/m) every 3 weeks (arm B)
Trial: 16756691
Drug: Bright-light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright-light therapy combined with sertraline
Trial: 16756691
Drug: Dim-light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim-light therapy combined with sertraline
Trial: 10994859
Drug: Dipyridamole 0.142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 0.142 mg/kg x min
Trial: 8865952
Drug: 4-Methylpyrazole (4-MP)
RxNorm normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-Methylpyrazole (4-MP) at doses of 10 to 20 mg/kg
Trial: 8865952
Drug: Ethanol (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.6 g/kg followed by 0.2 g/kg twice)
Trial: 9892329
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg warfarin
Trial: 30518334
Drug: Oral Fosfomycin-Trometamol
RxNorm normalized name: trometamol
DrugBank: Tromethamine (DB03754)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Fosfomycin-Trometamol 3000 mg (3 g every 24 h) for 10 days
Trial: 30518334
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg every 12 h for 10 days (standard of care)
Trial: 20697090
Drug: FC treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FC treatment arm
Trial: 2272259
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyperthermia and radiation (RH)
Trial: 2272259
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hyperthermia and radiation (HR)
Trial: 25646170
Drug: SRP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL
Trial: 19284928
Drug: Olanzapine/Fluoxetine Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine/Fluoxetine Combination (OFC)
Trial: 373099
Drug: Bendrofluazide (thiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide (thiazide diuretic)
Trial: 27744438
Drug: Vaginal probiotics
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal probiotics with antibiotic prophylaxis
Trial: 25931293
Drug: Antibiotics only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics only
Trial: 19255890
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (1,260 mg eicosapentaenoic acid and 540 mg docosahexaenoic acid/day)
Trial: 8546481
Drug: Three-pulse treatment
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-pulse treatment group (200 mg itraconazole twice daily for 1 week each month)
Trial: 8546481
Drug: Four-pulse treatment
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-pulse treatment group (200 mg itraconazole twice daily for 1 week each month)
Trial: 2063675
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (serum bilirubin < 12 mg/dl)
Trial: 3914859
Drug: Ceftazidime (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (500 mg intravenously every 12 h)
Trial: 3914859
Drug: Moxalactam (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam (500 mg intravenously every 12 h; 2 g for Pseudomonas aeruginosa)
Trial: 20423561
Drug: Anserine (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anserine (specific doses, intraperitoneal administration)
Trial: 20423561
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of anserine
Trial: 10512601
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily for up to 8 weeks with ERT
Trial: 10512601
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg daily for up to 8 weeks without ERT
Trial: 10512601
Drug: Fluoxetine responders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine responders treated up to 26 weeks
Trial: 8744879
Drug: Physicians provided
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physicians provided with Hamilton Depression rating scale (HAM-D) scores and patient-specific treatment recommendations
Trial: 25150954
Drug: Oral letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral letrozole (2.5mg/day) and norethindrone acetate (2.5mg/day) for three months prior to surgery (group A)
Trial: 25150954
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment before surgery (group B)
Trial: 21947680
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B (28-day cycles: capecitabine 1,000 mg/m2 twice daily, days 1-5, 8-12, and 15-19; paclitaxel 80 mg/m2, days 1, 8, and 15)
Trial: 15789590
Drug: Dose-Volume Histogram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-Volume Histogram (DVH)
Trial: 15789590
Drug: Dose-Surface Histogram
RxNorm normalized name: sulfacetamide sodium Ophthalmic Solution [Sulfac]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-Surface Histogram (DSH)
Trial: 12218390
Drug: Niacin, 3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin, 3000 mg/day for > or = 6 months
Trial: 10485774
Drug: Intravenous clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous clonidine (1 microg/kg)
Trial: 1992574
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (total androgen blockade with nilutamide)
Trial: 6606393
Drug: Moxalactam, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam, 250 mg every 12 h
Trial: 6606393
Drug: Gentamicin, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin, 1 mg/kg every 8 h
Trial: 26860641
Drug: Baseline creatinine
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline creatinine clearance <25 mL/min vs >65 mL/min
Trial: 26860641
Drug: Discharge on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge on low-molecular-weight heparin
Trial: 20433751
Drug: Phytotherapic compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytotherapic compound containing Pimpinella anisum, Foeniculum vulgare, Sambucus nigra, and Cassia augustifolia for 5 days
Trial: 18608063
Drug: Moderate-intensity exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-intensity exercise training (30 minutes of aerobic training followed by resistance training, twice weekly for six weeks)
Trial: 16787138
Drug: PDE5 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDE5 inhibitors
Trial: 12169865
Drug: L-threo-3,4-dihydroxyphenylserine (L-DOPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-threo-3,4-dihydroxyphenylserine (L-DOPS) 400 mg
Trial: 11961396
Drug: L-threo-3,4-dihydroxyphenylserine (L-DOPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-threo-3,4-dihydroxyphenylserine (L-DOPS) 200 mg
Trial: 7629406
Drug: naloxone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone (0.4 mg/kg)
Trial: 2393295
Drug: Amifloxacin 200
RxNorm normalized name: gatifloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifloxacin 200 mg q12h
Trial: 2393295
Drug: Amifloxacin 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifloxacin 600 mg q12h
Trial: 2393295
Drug: Amifloxacin 400
RxNorm normalized name: gatifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifloxacin 400 mg q8h
Trial: 2393295
Drug: Amifloxacin 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifloxacin 600 mg q8h
Trial: 2393295
Drug: Amifloxacin 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifloxacin 800 mg q8h
Trial: 2393295
Drug: Amifloxacin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifloxacin (all doses)
Trial: 2393295
Drug: Amifloxacin (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifloxacin (doses above 1200 mg/day)
Trial: 19496957
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium (70 mg/kg magnesium sulphate infusions in 4 hours for 5 days)
Trial: 19496957
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% solutions (control for blinding purposes)
Trial: 20047115
Drug: Rosiglitazone plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone plus metformin
Trial: 16957566
Drug: Glyburide plus
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide plus metformin
Trial: 3277398
Drug: Pharmacologic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic treatment of mild-to-moderate hypertension
Trial: 11772140
Drug: Sustained-release oral
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release oral morphine
Trial: 31124516
Drug: Retrobulbar block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar block with 0.5% ropivacaine plus dexmedetomidine 1 μg/kg (group RD, n = 20)
Trial: 16709204
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms of oral misoprostol
Trial: 3069206
Drug: Metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (200 mg daily for the first 3 months)
Trial: 29494417
Drug: Monthly high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly high-dose vitamin D3 (100,000 IU), n = 2041
Trial: 29494417
Drug: Monthly high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly high-dose vitamin D3 (100,000 IU) in vitamin D deficient participants (<50 nmol/L, 24.9%)
Trial: 24942404
Drug: LY2603618 (≥240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2603618 (≥240 mg) in combination with pemetrexed (500 mg/m²) and cisplatin (75 mg/m²)
Trial: 24942404
Drug: LY2603618 (130-275
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2603618 (130-275 mg) in combination with pemetrexed (500 mg/m²) and cisplatin (75 mg/m²)
Trial: 8617710
Drug: Haloperidol plus
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol plus sertraline (200 mg/day)
Trial: 8500374
Drug: Preoperative short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative short-term high-dose irradiation (25.5 Gy in one week)
Trial: 29704966
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) intervention, consisting of four 2.5-hour workshops over a 4-week period, with home exercises (e.g., meditation, observation grids)
Trial: 23269680
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab plus ablative therapy
Trial: 23269680
Drug: Ablative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative therapy alone
Trial: 15758000
Drug: Clopidogrel (300-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300-mg loading dose, followed by 75 mg once daily)
Trial: 1630347
Drug: Nebuhaler/MDI (metered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebuhaler/MDI (metered dose aerosol terbutaline)
Trial: 3934548
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum combined with behavioral treatment
Trial: 10048102
Drug: 14 mg
RxNorm normalized name: iodine 0.14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg nicotine patches
Trial: 18584466
Drug: placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patches
Trial: 2210608
Drug: Cisapride 40
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisapride 40 mg (q.i.d.)
Trial: 2210608
Drug: Cisapride 20
RxNorm normalized name: cisapride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 20 mg (b.i.d.)
Trial: 2210608
Drug: Cimetidine 1600
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine 1600 mg (q.i.d.)
Trial: 2210608
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg (b.i.d.)
Trial: 508701
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 500 mg/d
Trial: 508701
Drug: Calcium caseinate
RxNorm normalized name: calcium caseinate
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium caseinate 15 g/d
Trial: 31987544
Drug: Upper limb
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper limb Robot‐assisted Therapy (RT)
Trial: 31987544
Drug: Traditional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional physical Therapy (TT)
Trial: 19302904
Drug: Compliance device
RxNorm normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Compliance device with grass allergen tablets
Trial: 17391286
Drug: Simultaneous intervals
RxNorm normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous intervals for dose-finding trials
Trial: 15492300
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (3 g at least 2 hours before the procedure and 2 g in the night and the morning after the procedure)
Trial: 11235926
Drug: Olanzapine (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5, 10, or 15 mg/day)
Trial: 31939321
Drug: Cluster nursing
RxNorm normalized name: cluster fig extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cluster nursing measures in combination with continuous phototherapy (blue light)
Trial: 28576897
Drug: FAB and
RxNorm normalized name: DIGOXIN IMMUNE FAB
DrugBank: Digoxin Immune Fab (Ovine) (DB00076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAB and combination groups (food, activity and breastfeeding intervention)
Trial: 25942417
Drug: Gadolinium-based contrast
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium-based contrast agent (GBCA)
Trial: 25942417
Drug: Non-gadolinium-based contrast
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-gadolinium-based contrast agent (non-GBCA)
Trial: 21664710
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses (40-45Gy)
Trial: 9170037
Drug: sprodiamide injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sprodiamide injection at 0.1 mmol/kg
Trial: 9170037
Drug: sprodiamide injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sprodiamide injection at 0.2 mmol/kg
Trial: 9170037
Drug: sprodiamide injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sprodiamide injection at 0.3 mmol/kg
Trial: 9170037
Drug: sprodiamide injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sprodiamide injection at 0.1 mmol/kg at 2 ml/second
Trial: 9170037
Drug: sprodiamide injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sprodiamide injection at 0.2 mmol/kg at 2 ml/second
Trial: 9170037
Drug: sprodiamide injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sprodiamide injection at 0.3 mmol/kg at 2 ml/second
Trial: 9170037
Drug: sprodiamide injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sprodiamide injection at 0.1 mmol/kg at 5 ml/second
Trial: 9170037
Drug: sprodiamide injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sprodiamide injection at 0.2 mmol/kg at 5 ml/second
Trial: 9170037
Drug: sprodiamide injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sprodiamide injection
Trial: 1492860
Drug: Dihydroergocristine (DHEC)
RxNorm normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergocristine (DHEC) 3 ml drops (2 mg/ml)
Trial: 1492860
Drug: Dihydroergocristine (DHEC)
RxNorm normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergocristine (DHEC) single-dose bottle (6 mg)
Trial: 27931302
Drug: Ciclesonide 320
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide 320 microgram daily dose
Trial: 27931302
Drug: Ciclesonide 160
RxNorm normalized name: CICLESONIDE 160MCG 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 160 microgram daily combined with LABA (formoterol)
Trial: 27931302
Drug: Ciclesonide 160
RxNorm normalized name: CICLESONIDE 160MCG 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 160 microgram daily combined with LTRA (montelukast)
Trial: 27931302
Drug: Ciclesonide 160
RxNorm normalized name: CICLESONIDE 160MCG 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 160 microgram daily dose
Trial: 23183711
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bromocriptine and sulpiride
Trial: 12456421
Drug: Ketamine 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 3.0 or 3.5 mg/kg with lidocaine spray
Trial: 10479851
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 cc of physiological infusion administered in the same manner)
Trial: 6958487
Drug: Becotide Nasal
RxNorm normalized name: BECOTIN CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Becotide Nasal (400 micrograms daily, administered four times a day)
Trial: 26868369
Drug: Inhaled mometasone
RxNorm normalized name: mometasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled mometasone
Trial: 19942107
Drug: Yoga sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga sessions lasting 60 min daily
Trial: 19942107
Drug: Brief supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief supportive therapy once in 10 days
Trial: 15782505
Drug: Neostigmine (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.02 mg/kg) and atropine (0.01 mg/kg) infusion in group C and group D after neuromuscular recovery (T1/T(C)) reached 10%.
Trial: 15782505
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (MgSO4) 30 mg/kg in saline intravenously within 5 min in group A and group C.
Trial: 15782505
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion in group B and group D.
Trial: 15782505
Drug: Neostigmine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine and atropine infusion in group C and group D.
Trial: 8583661
Drug: Acetated Ringer
RxNorm normalized name: ACETATED RINGER'S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated Ringer (AR) solution
Trial: 8583661
Drug: Lactated Ringer
RxNorm normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer (LR) solution
Trial: 1681365
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of Ty21a vaccine
Trial: 90214
Drug: Methadone (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (average 97 mg/day, range 30-130 mg)
Trial: 90214
Drug: Placebo (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (with gradual reduction of methadone at 1 mg/day)